Abstract:

Additive tissue has increased interest in the bioactive factors it dissolves with the understanding that it is not only a passive energy warehouse, but also an endocrine organ. In addition to the adiposites, the adiposite tissue, which consists of pre-adipocytes, macrophages, endothelial cells, fibroblasts and leukocytes, has an important role in the systemic metabolic regulation. Tazarotene-induced gen 2 (TIG2) or retinoic acid receptor responsive 2 (RARRES2) chemerin was first discovered in 1997 in psoriatic skin lesions, as a retinoic acid-sensitive gen. It was then identified and classified as an adipogenesis and adiposite metabolism by data showing that chemerin changes adiposite differentiation, the expression of important genes in glucose and lipite metabolism and is a new adipokine. The effect of Chemerin on circulation and inflammatory fluids is mediated by the receptor G protein-related receptor through the chemokin-like receptor 1 (CMKLR1). Obesity, metabolic syndrome (MetS), type 2 diabetes (T2DM), from polycystic over syndrome (PKOS) to inflammatory diseases, the increase in the number of clinical studies associated with the increase in local and/or circulatory chemerin levels in various diseases supports the important role of chemerin in the pathogenesis of these diseases. Although it is clear that the levels of serum chemerine are increasing in these diseases, the mechanisms that regulate the expression of chemerine have not been fully understood. More randomized controlled work is needed to understand the mechanisms of action of chemerin.